T-cell receptor-like antibodies: Novel reagents for clinical cancer immunology and immunotherapy

Roy Noy, Malka Epel, Maya Haus-Cohen, Eynav Klechevsky, Oryan Makler, Yael Michaeli, Galit Denkberg, Yoram Reiter

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Major histocompatibility complex class I molecules play a central role in the immune response against a variety of cells that have undergone malignant transformation by shaping the T-cell repertoire and presenting peptide antigens from endogeneous antigens to CD8+ cytotoxic T-cells. Diseased tumor or virus-infected cells are present on class I major histocompatibility complex molecule peptides that are derived from tumor-associated antigens or viral-derived proteins. Due to their unique specifity, such major histocompatibility complex-peptide complexes are a desirable target for novel approaches in immunotherapy. Targeted delivery of toxins or other cytotoxic drugs to cells which express specific major histocompatibility complex-peptide complexes that are involved in the immune response against cancer or viral infections would allow for a specific immunotherapeutic treatment of these diseases. It has recently been demonstrated that antibodies with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells can be generated by taking advantage of the selection power of phage display technology. In addition to their tumor targeting capabilities, antibodies that mimic the fine specificity of T-cell receptors can serve as valuable research reagents that enable study of human class I peptide-major histocompatibility complex ligand presentation, as well as T-cell receptor peptide-major histocompatibility complex interactions. T-cell receptor-like antibody molecules may prove to be useful tools for studying major histocompatibility complex class I antigen presentation in health and disease as well as for therapeutic purposes in cancer, infectious diseases and autoimmune disorder.

Original languageEnglish
Pages (from-to)523-536
Number of pages14
JournalExpert Review of Anticancer Therapy
Issue number3
StatePublished - Jun 2005


  • Antibodies
  • Antibody engineering
  • Cancer immunotherapy
  • Immunotoxins
  • Major histocompatibility complex-peptide complex
  • Phage display
  • Recombinant antibodies
  • T-cell receptor


Dive into the research topics of 'T-cell receptor-like antibodies: Novel reagents for clinical cancer immunology and immunotherapy'. Together they form a unique fingerprint.

Cite this